EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutation is one of the most common oncogenic mutations in NSCLC.2 Based on the phase III FLAURA study,3 third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib has been recommended as preferred first-line treatment for patients with EGFR-mutant advanced NSCLC.